Shabir Madhi

Shabir Madhi is a prominent South African vaccinologist and infectious disease expert. He is known for his extensive research in the field of vaccinology, particularly in the development and testing of vaccines for pneumococcal disease, rotavirus, and more recently, COVID-19.
Early Life and Education[edit]
Shabir Madhi was born in South Africa. He completed his medical degree at the University of the Witwatersrand in Johannesburg. He later pursued a specialization in pediatrics and obtained a PhD in vaccinology.
Career[edit]
Madhi has held several key positions in the field of infectious diseases and vaccinology. He is a professor of vaccinology at the University of the Witwatersrand and the Executive Director of the South African Medical Research Council's Vaccines and Infectious Diseases Analytics Research Unit (VIDA).
He has been involved in numerous clinical trials and has contributed significantly to the understanding and prevention of infectious diseases in Africa. His work has been instrumental in the introduction of the pneumococcal conjugate vaccine and the rotavirus vaccine into the South African national immunization program.
COVID-19 Research[edit]
During the COVID-19 pandemic, Madhi played a crucial role in the clinical trials for the Oxford-AstraZeneca COVID-19 vaccine in South Africa. His research provided important insights into the efficacy of the vaccine against the Beta variant of the virus, which was first identified in South Africa.
Awards and Recognition[edit]
Shabir Madhi has received numerous awards for his contributions to medical science and public health. He is a member of several prestigious organizations, including the Academy of Science of South Africa.
Publications[edit]
Madhi has authored and co-authored numerous scientific papers in high-impact journals. His research has significantly influenced public health policies and vaccine strategies in South Africa and globally.
Related Pages[edit]
- Vaccinology
- Infectious disease
- Pneumococcal disease
- Rotavirus
- COVID-19 pandemic
- Oxford-AstraZeneca COVID-19 vaccine
- University of the Witwatersrand
- South African Medical Research Council
References[edit]
External Links[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian